Concurrent DNA hypomethylation and epigenomic reprogramming driven by androgen receptor binding in bladder cancer oncogenesis

Yu Xiao; Lingao Ju; Wan Jin; Hongwei Peng; Zongning Zhou; Mengxue Yu; Zilin Xu; Gang Wang; Kaiyu Qian; Yi Zhang; Xinghuan Wang

doi:10.1002/ctm2.70153

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (1) : e70153 DOI: 10.1002/ctm2.70153

LETTER TO THE JOURNAL

Concurrent DNA hypomethylation and epigenomic reprogramming driven by androgen receptor binding in bladder cancer oncogenesis

Yu Xiao ¹^,²
, Lingao Ju ²^,³
, Wan Jin ²^,⁴
, Hongwei Peng ²
, Zongning Zhou ²
, Mengxue Yu ²^,³
, Zilin Xu ²
, Gang Wang ¹^,²
, Kaiyu Qian ²^,³^,^†
, Yi Zhang ⁴^,⁵^,^†
, Xinghuan Wang ¹^,⁶^,⁷^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Yu Xiao, Lingao Ju, Wan Jin, Hongwei Peng, Zongning Zhou, Mengxue Yu, Zilin Xu, Gang Wang, Kaiyu Qian, Yi Zhang, Xinghuan Wang. Concurrent DNA hypomethylation and epigenomic reprogramming driven by androgen receptor binding in bladder cancer oncogenesis. Clinical and Translational Medicine, 2025, 15(1): e70153 DOI:10.1002/ctm2.70153

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Xiao Y, Jin W, Ju L, et al. Tracking single-cell evolution using clock-like chromatin accessibility loci [published online ahead of print May 9, 2024]. Nat Biotechnol.

[2]	Xiao Y, Jin W, Qian K, et al. Integrative single cell atlas revealed intratumoral heterogeneity generation from an adaptive epigenetic cell state in human bladder urothelial carcinoma. Adv Sci. 2024;11(24):e2308438.

[3]	Kim E, Choi S, Kang B, et al. Creation of bladder assembloids mimicking tissue regeneration and cancer. Nature. 2020;588(7839):664-669.

[4]	Teng M, Zhou S, Cai C, Lupien M, He HH. Pioneer of prostate cancer: past, present and the future of FOXA1. Protein Cell. 2021;12(1):29-38.

[5]	Dobruch J, Daneshmand S, Fisch M, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol. 2016;69(2):300-310.

[6]

Safiri S, Kolahi AA, Naghavi M, Global Burden of Disease Bladder Cancer Collaborators. Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019. BMJ Glob Health. 2021;6(11):e004128.

[7]	Radkiewicz C, Edgren G, Johansson ALV, et al. Sex differences in urothelial bladder cancer survival. Clin Genitourin Cancer. 2020;18(1):26-34.e6.

[8]	Hyldgaard JM, Jensen JB. The inequality of females in bladder cancer. APMIS. 2021;129(12):694-699.

[9]	Chen J, Huang CP, Quan C, et al. The androgen receptor in bladder cancer. Nat Rev Urol. 2023;20(9):560-574.

[10]	Xiao Y, Ju L, Qian K, et al. Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study. Clin Transl Med. 2022;12(8):e1008.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.